Nestlé re­con­sid­ers peanut al­ler­gy pro­gram two years af­ter $2.6B buy­out

It seems Nestlé is ex­pe­ri­enc­ing some buy­er’s re­morse two years af­ter throw­ing down $2.6 bil­lion for Aim­mune Ther­a­peu­tics and its peanut al­ler­gy pill Pal­forzia.

CEO Mark Schnei­der an­nounced on Tues­day that Nestlé is “ex­plor­ing strate­gic op­tions” for Pal­forzia fol­low­ing low­er-than-ex­pect­ed de­mand. A com­pa­ny spokesper­son de­clined to con­firm whether a po­ten­tial sale is in con­sid­er­a­tion.

“The re­view is ex­pect­ed to be com­plet­ed in the first half of 2023. Go­ing for­ward, Nestlé Health Sci­ence will sharp­en its fo­cus on Con­sumer Care and Med­ical Nu­tri­tion,” the com­pa­ny said in a news re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER